AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9564393 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 9564393 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 60
Study 9564393 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Propofol and Thiopentone
Number of subjects: 60
Study 8082451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine devices (IUD)
Number of subjects: 285
Study 8082451 — intervention group
Group type: COMPARATOR
Intervention: Non-IUD
Number of subjects: 285
Study 2681022 — intervention group
Group type: EXPERIMENTAL
Intervention: International comparisons of patterns, trends, and determinants of CHD mortality
Number of subjects: 0
Study 1161345 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium lactate, 800 mg/kg/24 hr in divided doses with each feed (group B)
Number of subjects: 30
Study 1161345 — intervention group
Group type: COMPARATOR
Intervention: No calcium supplement (group A)
Number of subjects: 30
Study 31689708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (160 U)
Number of subjects: 15
Study 31689708 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 15
Study 30342026 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar hemostatic forceps soft coagulation (MHFSC)
Number of subjects: 112
Study 30342026 — intervention group
Group type: COMPARATOR
Intervention: Hemoclips (HC)
Number of subjects: 112
Study 28344345 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (EX)
Number of subjects: 22
Study 28344345 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 22
Study 25884810 — intervention group
Group type: EXPERIMENTAL
Intervention: History of foster care placement
Number of subjects: 442
Study 25884810 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 442
Study 24248687 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (Arm A)
Number of subjects: 306
Study 24248687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Lapatinib and Trastuzumab (Arm C)
Number of subjects: 306
Study 20603436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 572
Study 19357536 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual low dose CT scans for 5 years
Number of subjects: 4104
Study 19357536 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 4104
Study 17846074 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls prevention exercise programme
Number of subjects: 0
Study 17846074 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study 15480130 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative Therapy (MT)
Number of subjects: 240
Study 15480130 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential Therapy (IFT)
Number of subjects: 240
Study 15480130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Therapy (CT)
Number of subjects: 240
Study 11782693 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal approach
Number of subjects: 20
Study 11782693 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 20
Study 9507846 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat sextant prostate biopsy
Number of subjects: 118
Study 9507846 — intervention group
Group type: COMPARATOR
Intervention: Initial clinical stage
Number of subjects: 118
Study 8062353 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan
Number of subjects: 18
Study 8062353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29068153 — intervention group
Group type: EXPERIMENTAL
Intervention: ciNPT (PREVENA™ Therapy)
Number of subjects: 100
Study 29068153 — intervention group
Group type: COMPARATOR
Intervention: Control dressing (conventional adhesive plaster)
Number of subjects: 100
Study 26413789 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 2
Study 26413789 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 2
Study 26413789 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 2
Study 24535360 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol TCI + 0.8 μg/kg fentanyl
Number of subjects: 58
Study 24535360 — intervention group
Group type: COMPARATOR
Intervention: Propofol TCI + 40 mg lidocaine
Number of subjects: 58
Study 22762231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive quit‐smoking intervention (n = 148)
Number of subjects: 263
Study 22762231 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 115)
Number of subjects: 263
Study 20584655 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVH plus CPFA
Number of subjects: 30
Study 20584655 — intervention group
Group type: COMPARATOR
Intervention: CVVH alone
Number of subjects: 30
Study 17889865 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification by the Cryotop method
Number of subjects: 60
Study 17072055 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids for 2 months
Number of subjects: 41
Study 12858196 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood stem cells (BSC)
Number of subjects: 61
Study 12858196 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow (BM)
Number of subjects: 61
Study 10831691 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (Gd‐BOPTA) 0.05‐mmol/kg dose administered before and after imaging
Number of subjects: 214
Study 10831691 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (Gd‐BOPTA) 0.1‐mmol/kg dose administered before and after imaging
Number of subjects: 214
Study 10831691 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (Gd‐BOPTA)
Number of subjects: 214
Study 8800891 — intervention group
Group type: EXPERIMENTAL
Intervention: No antibiotics perioperatively (Group I)
Number of subjects: 116
Study 8800891 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole for 5 days (Group II)
Number of subjects: 116
Study 1997058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of unlimited clear fluids up to 3 h before surgery
Number of subjects: 152
Study 1997058 — intervention group
Group type: COMPARATOR
Intervention: Nothing by mouth after midnight (control group)
Number of subjects: 152
Study 6229892 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 0
Study 6229892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 0
Study 6229892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 0
Study 6229892 — intervention group
Group type: EXPERIMENTAL
Intervention: Lincomycin
Number of subjects: 0
Study 6229892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6229892 — intervention group
Group type: COMPARATOR
Intervention: Rifampin
Number of subjects: 0
Study 29589991 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Campaigns (CHCs)
Number of subjects: 12
Study 29589991 — intervention group
Group type: COMPARATOR
Intervention: Government Clinics
Number of subjects: 12
Study 27220574 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation using domestic 3D cardiac electrophysiological mapping system
Number of subjects: 255
Study 27220574 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmics drugs cardioversion
Number of subjects: 255
Study 24764640 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 30
Study 24764640 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 30
Study 22872251 — intervention group
Group type: EXPERIMENTAL
Intervention: Christmas tree foreheadplasty with supraorbital bandeau
Number of subjects: 32
Study 22872251 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched normal controls)
Number of subjects: 32
Study 20148906 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day)
Number of subjects: 49
Study 20148906 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 49
Study 20148906 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day) and Diet alone
Number of subjects: 49
Study 18597226 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 56
Study 18597226 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard propofol titration)
Number of subjects: 56
Study 15780550 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 116
Study 15780550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 12018972 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol (1305 mg)
Number of subjects: 85
Study 10622070 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg) every 12 hours for 5-10 days
Number of subjects: 125
Study 10622070 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin (3 MIU) every 12 hours for 5-10 days
Number of subjects: 125
Study 7575745 — intervention group
Group type: EXPERIMENTAL
Intervention: New sotalol hydrochloride tablet (160 mg)
Number of subjects: 16
Study 1835157 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal flexion exercises
Number of subjects: 0
Study 1835157 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal extension exercises
Number of subjects: 0
Study 1835157 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 6128546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral captopril
Number of subjects: 16
Study 6128546 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin infusion
Number of subjects: 16
Study 31055522 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential learning in communication skills training
Number of subjects: 20
Study 30026514 — intervention group
Group type: EXPERIMENTAL
Intervention: Jerusalem artichoke and fermented soybean powder mixture (40g daily for 12 weeks)
Number of subjects: 60
Study 27528117 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen suppression (secondary treatment)
Number of subjects: 176
Study 27528117 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of bony metastatic sites
Number of subjects: 176
Study 27528117 — intervention group
Group type: EXPERIMENTAL
Intervention: Other sites of progression
Number of subjects: 176
Study 27528117 — intervention group
Group type: EXPERIMENTAL
Intervention: Further bony metastatic progression in men with up to 3 bony metastases
Number of subjects: 176
Study 26875300 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ferric EDTA (2.5 mg of iron)
Number of subjects: 139
Study 26875300 — intervention group
Group type: COMPARATOR
Intervention: High-dose ferrous lactate (10 mg of iron)
Number of subjects: 139
Study 26875300 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 139
Study 22424608 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire included in the invitation package
Number of subjects: 500
Study 22424608 — intervention group
Group type: COMPARATOR
Intervention: No questionnaire included in the invitation package
Number of subjects: 500
Study 19767320 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokefree Class Competition (intervention group)
Number of subjects: 3123
Study 19767320 — intervention group
Group type: COMPARATOR
Intervention: Control group (classes that refrained from smoking)
Number of subjects: 3123
Study 18697192 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid solution inducing hyperammonemia
Number of subjects: 16
Study 18697192 — intervention group
Group type: COMPARATOR
Intervention: Phosphate-buffered saline (control)
Number of subjects: 16
Study 18697192 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microM ammonia
Number of subjects: 16
Study 18697192 — intervention group
Group type: EXPERIMENTAL
Intervention: p38(MAPK) agonist
Number of subjects: 16
Study 15813840 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg intravenous bolus followed by oral ondansetron 8 mg twice daily for 5 days
Number of subjects: 19
Study 15813840 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 12560224 — intervention group
Group type: EXPERIMENTAL
Intervention: New designs for phase 2 clinical trials
Number of subjects: 0
Study 12560224 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized selection trials evaluating several therapies based on multiple outcomes
Number of subjects: 0
Study 10728540 — intervention group
Group type: EXPERIMENTAL
Intervention: Toughened glassware
Number of subjects: 1229
Study 10728540 — intervention group
Group type: COMPARATOR
Intervention: Annealed glassware (control)
Number of subjects: 1229
Study 9446305 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalations of hydrogen sulfide water
Number of subjects: 77
Study 9446305 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen (controls)
Number of subjects: 77
Study 8478660 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-containing therapy (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 415
Study 8478660 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-containing therapy (CHOP)
Number of subjects: 415
Study 8478660 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 415
Study 3092659 — intervention group
Group type: EXPERIMENTAL
Intervention: enprostil (35 micrograms twice daily)
Number of subjects: 369
Study 3092659 — intervention group
Group type: COMPARATOR
Intervention: cimetidine (400 mg twice daily)
Number of subjects: 369
Study 3092659 — intervention group
Group type: EXPERIMENTAL
Intervention: enprostil
Number of subjects: 369
Study 3092659 — intervention group
Group type: COMPARATOR
Intervention: cimetidine
Number of subjects: 369
Study 30379624 — intervention group
Group type: EXPERIMENTAL
Intervention: Documented cardiotoxicity during on-protocol therapy
Number of subjects: 1022
Study 30379624 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident cardiotoxicity event in absence of infection
Number of subjects: 1022
Study 30379624 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident cardiotoxicity event in presence of infection
Number of subjects: 1022
Study 30379624 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-infection associated cardiotoxicity
Number of subjects: 1022
Study 30379624 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection-associated cardiotoxicity
Number of subjects: 1022
Study 30630782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 140
Study 30630782 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate
Number of subjects: 140
Study 27479339 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM splint
Number of subjects: 48
Study 27479339 — intervention group
Group type: COMPARATOR
Intervention: Conventional splint
Number of subjects: 48
Study 27479339 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 48
Study 24790826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block with bupivacaine
Number of subjects: 140
Study 24790826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 23342679 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A plus upper limb therapy programme
Number of subjects: 333
Study 23342679 — intervention group
Group type: COMPARATOR
Intervention: Upper limb therapy programme alone
Number of subjects: 333
Study 23342679 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A plus therapy
Number of subjects: 333
Study 21196929 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg/day)
Number of subjects: 21
Study 21196929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 16703311 — intervention group
Group type: COMPARATOR
Intervention: iomeprol 300 (iodine concentration: 300 mg/ml)
Number of subjects: 21
Study 16703311 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol 400 (iodine concentration: 400 mg/ml)
Number of subjects: 21
Study 16076919 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly plus calcium carbonate 500 mg daily
Number of subjects: 58
Study 16076919 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate 500 mg daily
Number of subjects: 58
Study 11998525 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatopharyngeal surgery (four different surgical techniques)
Number of subjects: 0
Study 10407719 — intervention group
Group type: EXPERIMENTAL
Intervention: Surviving Cancer Competently Intervention Program (SCCIP) - a one-day family group intervention combining cognitive-behavioral and family therapy approaches
Number of subjects: 19
Study 10407719 — intervention group
Group type: EXPERIMENTAL
Intervention: Surviving Cancer Competently Intervention Program (SCCIP)
Number of subjects: 19
Study 7761740 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 19
Study 7761740 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation with Continuous Physical Work (SDW)
Number of subjects: 19
Study 7761740 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD) and Sleep Deprivation with Continuous Physical Work (SDW)
Number of subjects: 19
Study 1967946 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium
Number of subjects: 43
Study 1967946 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium
Number of subjects: 43
Study 6767517 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 50 g of mannitol 2 hours before whole bowel irrigation (WBI)
Number of subjects: 42
Study 6767517 — intervention group
Group type: COMPARATOR
Intervention: Whole bowel irrigation (WBI) alone
Number of subjects: 42
Study 28741061 — intervention group
Group type: EXPERIMENTAL
Intervention: CM formula (10 herbs) for 4 weeks
Number of subjects: 122
Study 28741061 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics for 1 week followed by 3 weeks of placebo
Number of subjects: 122
Study 27918731 — intervention group
Group type: EXPERIMENTAL
Intervention: Passiflora incarnata (260 mg)
Number of subjects: 40
Study 27918731 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 40
Study 25140866 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg guanfacine (n=50)
Number of subjects: 84
Study 25140866 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=34)
Number of subjects: 84
Study 23370985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary (IM) repair
Number of subjects: 30
Study 23370985 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate repair
Number of subjects: 30
Study 23370985 — intervention group
Group type: EXPERIMENTAL
Intervention: IM device removal
Number of subjects: 30
Study 23370985 — intervention group
Group type: COMPARATOR
Intervention: Plate removal
Number of subjects: 30
Study 23370985 — intervention group
Group type: COMPARATOR
Intervention: Intact clavicle
Number of subjects: 30
Study 23470990 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 25
Study 23470990 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 25
Study 20334477 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 6 hours after a rice meal (R6)
Number of subjects: 212
Study 20334477 — intervention group
Group type: COMPARATOR
Intervention: Fasting for 10 hours after a rice meal (R10)
Number of subjects: 212
Study 17669545 — intervention group
Group type: EXPERIMENTAL
Intervention: Kids Choice Program
Number of subjects: 0
Study 16419687 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium enoxaparin, administered subcutaneously at a dose of 2,000 IU twice daily for 10 days
Number of subjects: 30
Study 16419687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12049575 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication
Number of subjects: 0
Study 12049575 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline factors (age, cup-disc ratio, intraocular pressure, pattern standard deviation, central corneal thickness)
Number of subjects: 0
Study 9443710 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide T (2 mg, intranasally, 3 times a day for 6 months)
Number of subjects: 0
Study 9443710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8544654 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark-blood MRI with semiautomated image processing
Number of subjects: 4
Study 8544654 — intervention group
Group type: COMPARATOR
Intervention: Bright-blood MRA
Number of subjects: 4
Study 8544654 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark-blood MRI
Number of subjects: 4
Study 2677429 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 229
Study 7152082 — intervention group
Group type: EXPERIMENTAL
Intervention: Disophrol Syrup
Number of subjects: 78
Study 7152082 — intervention group
Group type: COMPARATOR
Intervention: Rinomar Syrup
Number of subjects: 78
Study 31628085 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensartinib 225 mg orally once daily
Number of subjects: 160
Study 30990762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise programme (60-minute sessions for 12 weeks)
Number of subjects: 110
Study 30990762 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 110
Study 28393439 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a
Number of subjects: 9
Study 28393439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 26508711 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 1790
Study 23652578 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of ranibizumab monthly for 12 months
Number of subjects: 37
Study 23652578 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of ranibizumab monthly for 3 months and then pro re nata
Number of subjects: 37
Study 23652578 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose 2.0 mg of ranibizumab monthly for 12 months
Number of subjects: 37
Study 23652578 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg of ranibizumab monthly for 3 months and then pro re nata thereafter
Number of subjects: 37
Study 23652578 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 37